Table 1

Baseline characteristics of the included patients with SLE

CharacteristicsWomen with SLE (n=12)
ACR criteria*
 Malar rash3 (25)
 Discoid rash2 (16)
 Photosensitivity4 (33)
 Oral ulcers3 (25)
 Arthritis10 (83)
 Serositis1 (8.3)
 Renal disorder7 (58)
 Neurological disorder0 (0)
 Haematological disorder6 (50)
 Immunological disorder9 (75)
 ANA12 (100)
Disease duration at inclusion (years)†8.5 (0.5–15)
SLEDAI-2K score during pregnancy†‡1 (0–2)
Ever anti-dsDNA*10 (83)
Ever antiphospholipid antibodies*§5 (42)
Antiphospholipid syndrome*0 (0)
Medication at pregnancy onset*
 Hydroxychloroquine11 (92)
 Low molecular weight heparin¶6 (50)
 Acetylsalicylic acid¶12 (100)
 Any immunosuppressant medication**11 (92)
 Azatioprin5 (42)
 Prednisone5†† (42)
  • *Data presented as n (%).

  • †Data presented as median (range).

  • ‡Missing data for four participants.

  • §Including anti-β2-glycoprotein 1 antibody (IgA, IgG and IgM), anticardiolipin antibody (IgA, IgG and IgM) and lupus anticoagulans (dRVVT).

  • ¶LMWH in four patients at pregnancy start and an additional two patients during pregnancy. Acetylsalicylic acid in nine patients at pregnancy start and an additional three patients during pregnancy.

  • **Including azatioprin and prednisone.

  • ††Dose range 2.5–5.0 mg/day.

  • ACR, American College of Rheumatology; SLEDAI-2K, Systemic Lupus Disease Activity Index 2000.